GlassScriptPhysician profile
Jonathan Philip Elias
NPI 1366682254
$1,892.28
in general payments reported to CMS, 2019-2025
23 companies · $387 in 2025
The $387 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $239 · 2021: $315 · 2022: $241 · 2023: $303 · 2024: $305 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $375.98 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $264.53 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $199.80 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $190.44 | 2019-2024 | Jornay Pm |
| Amarin Pharma, INC. | $126.32 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $93.96 | 2021-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $91.15 | 2019-2023 | Bexsero |
| Seqirus USA INC | $68.08 | 2021-2024 | Flucelvax Quadrivalent, Flucelvax |
| Astellas Pharma US INC | $65.93 | 2025 | Veozah |
| Tris Pharma INC | $61.65 | 2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $45.94 | 2025 | Jornay Pm |
| Pfizer INC. | $43.60 | 2019-2020 | |
| Sobi, INC | $42.10 | 2021-2022 | |
| Sanofi Pasteur INC. | $39.78 | 2021-2025 | |
| Ultragenyx Pharmaceutical INC. | $39.18 | 2022-2024 | Dojolvi |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $28.41 | 2024 | |
| Boston Scientific Corporation | $25.41 | 2022 | |
| Abiomed | $22.67 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $16.28 | 2024 | Flumist Quadrivalent |
| Shire North American Group INC | $14.00 | 2019 | |
| Medtronic, INC. | $13.55 | 2024 | Closurefast |
| Genentech USA, INC. | $12.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Elias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.